Evidence map›Paper›PMID 36895440›Full record

ReviewBeilstein journal of nanotechnology2023

Recent progress in cancer cell membrane-based nanoparticles for biomedical applications.

Qixiong Lin, Yueyou Peng, Yanyan Wen, Xiaoqiong Li, Donglian Du, Weibin Dai, Wei Tian, Yanfeng Meng

Abstract readReview
In one paragraph

Review in Beilstein journal of nanotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Application of nanomedicines in tumor immunotherapy.Journal of molecular cell biology · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qixiong Lin *The Ninth Clinical Medical School of Shanxi Medical University, Taiyuan, Shanxi 030009, China.ORCID https://orcid.org/0000-0001-6767-2555
Yueyou Peng *Department of MRI, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, Shanxi 030009, China.
Yanyan WenSchool of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Xiaoqiong LiDepartment of MRI, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, Shanxi 030009, China.
Donglian DuDepartment of MRI, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, Shanxi 030009, China.
Weibin DaiDepartment of MRI, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, Shanxi 030009, China.
Wei TianDepartment of General Surgery, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi 030024, China.ORCID https://orcid.org/0000-0003-2398-5968
Yanfeng MengDepartment of MRI, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, Shanxi 030009, China.ORCID https://orcid.org/0000-0002-4992-1631

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune clearance and insufficient targeting have limited the efficacy of existing therapeutic strategies for cancer. Toxic side effects and individual differences in response to treatment have further limited the benefits of clinical treatment for patients. Biomimetic cancer cell membrane-based nanotechnology has provided a new approach for biomedicine to overcome these obstacles. Biomimetic nanoparticles exhibit various effects (e.g., homotypic targeting, prolonging drug circulation, regulating the immune system, and penetrating biological barriers) after encapsulation by cancer cell membranes. The sensitivity and specificity of diagnostic methods will also be improved by utilizing the properties of cancer cell membranes. In this review, different properties and functions of cancer cell membranes are presented. Utilizing these advantages, nanoparticles can exhibit unique therapeutic capabilities in various types of diseases, such as solid tumors, hematological malignancies, immune system diseases, and cardiovascular diseases. Furthermore, cancer cell membrane-encapsulated nanoparticles show improved effectiveness and efficiency in combination with current diagnostic and therapeutic methods, which will contribute to the development of individualized treatments. This strategy has promising clinical translation prospects, and the associated challenges are discussed.

Indexed as

cancer cell biomimeticsnanoparticlesprecision medicinetargeted therapytheranostic nanomedicine

Identifiers

PMID36895440
PMCPMC9989677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.